Literature DB >> 18649613

Diabetic foot infection.

Mazen S Bader1.   

Abstract

Foot infections are common in patients with diabetes and are associated with high morbidity and risk of lower extremity amputation. Diabetic foot infections are classified as mild, moderate, or severe. Gram-positive bacteria, such as Staphylococcus aureus and beta-hemolytic streptococci, are the most common pathogens in previously untreated mild and moderate infection. Severe, chronic, or previously treated infections are often polymicrobial. The diagnosis of diabetic foot infection is based on the clinical signs and symptoms of local inflammation. Infected wounds should be cultured after debridement. Tissue specimens obtained by scraping the base of the ulcer with a scalpel or by wound or bone biopsy are strongly preferred to wound swabs. Imaging studies are indicated for suspected deep soft tissue purulent collections or osteomyelitis. Optimal management requires aggressive surgical debridement and wound management, effective antibiotic therapy, and correction of metabolic abnormalities (mainly hyperglycemia and arterial insufficiency). Treatment with antibiotics is not required for noninfected ulcers. Mild soft tissue infection can be treated effectively with oral antibiotics, including dicloxacillin, cephalexin, and clindamycin. Severe soft tissue infection can be initially treated intravenously with ciprofloxacin plus clindamycin; piperacillin/tazobactam; or imipenem/cilastatin. The risk of methicillin-resistant S. aureus infection should be considered when choosing a regimen. Antibiotic treatment should last from one to four weeks for soft tissue infection and six to 12 weeks for osteomyelitis and should be followed by culture-guided definitive therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18649613

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  31 in total

1.  Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening for Patients with a Diabetic Foot Infection.

Authors:  Kari A Mergenhagen; Michael Croix; Kaitlyn E Starr; John A Sellick; Alan J Lesse
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Topical nicotinic receptor activation improves wound bacterial infection outcomes and TLR2-mediated inflammation in diabetic mouse wounds.

Authors:  Mari Kishibe; Tina M Griffin; Melissa Goslawski; James Sinacore; Sascha A Kristian; Katherine A Radek
Journal:  Wound Repair Regen       Date:  2018-10-24       Impact factor: 3.617

3.  Evaluation of the Surgical and Pharmacological Treatment of Diabetic Foot Infection: A Retrospective Study.

Authors:  Adil Hassan Aliakbar; Malath Azeez Alsaadi; Abbas Abd Zaid Barrak
Journal:  Open Access Maced J Med Sci       Date:  2019-05-14

4.  Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost.

Authors:  B A Lipsky; Y P Tabak; R S Johannes; L Vo; L Hyde; J A Weigelt
Journal:  Diabetologia       Date:  2010-02-10       Impact factor: 10.122

5.  Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study.

Authors:  Matthew J Labreche; Grace C Lee; Russell T Attridge; Eric M Mortensen; Jim Koeller; Liem C Du; Natalie R Nyren; Lucina B Treviño; Sylvia B Treviño; Joel Peña; Michael W Mann; Abilio Muñoz; Yolanda Marcos; Guillermo Rocha; Stella Koretsky; Sandra Esparza; Mitchell Finnie; Steven D Dallas; Michael L Parchman; Christopher R Frei
Journal:  J Am Board Fam Med       Date:  2013 Sep-Oct       Impact factor: 2.657

6.  The utility of Gram stains and culture in the management of limb ulcers in persons with diabetes.

Authors:  Zulfiqarali G Abbas; Janet K Lutale; Mapoko M Ilondo; Lennox K Archibald
Journal:  Int Wound J       Date:  2012-02-01       Impact factor: 3.315

7.  Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care.

Authors:  Tatiana N Demidova-Rice; Michael R Hamblin; Ira M Herman
Journal:  Adv Skin Wound Care       Date:  2012-07       Impact factor: 2.347

8.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

Review 9.  The treatment of diabetic foot infections: focus on ertapenem.

Authors:  Michael Edmonds
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

Review 10.  The Diabetic Foot: A Historical Overview and Gaps in Current Treatment.

Authors:  Caroline C L M Naves
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-05-01       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.